Bosutinib contraindications and people who should use it with caution

Bosutinib (Bosutinib), as a potent tyrosine kinase inhibitor, has shown significant efficacy in the treatment of chronic Ph+ chronic myelogenous leukemia (CML). It provides an important treatment option for newly diagnosed patients, patients who are resistant or intolerant to previous treatments, and even for patients in the accelerated or blast phase. However, before using bosutinib, it is crucial to understand its contraindications and who should use it with caution.

1. Contraindications:

Patients who are allergic to bosutinib or any of its components should avoid using this drug. Anaphylaxis may include severe symptoms such as rash, difficulty breathing, and laryngeal edema, and may even be life-threatening.

2. People who should use it with caution:

1. Elderly people: Due to possible problems such as decreased liver and kidney function and slowed drug metabolism in the elderly, special caution is required when using bosutinib, and the dose may need to be adjusted. The doctor will develop a personalized medication plan based on the patient's specific condition and liver and kidney function.

2. Pregnant and lactating women: Bosutinib may have adverse effects on the fetus and infant, so pregnant and lactating women should use it with caution. Before using bosutinib, female patients should take a pregnancy test and use effective contraception during treatment and for 2 weeks after the last dose. If you become pregnant unexpectedly during treatment, you should tell your doctor immediately. Nursing women should avoid breastfeeding during treatment.

3. Patients with liver damage: Patients with liver damage should use bosutinib with caution. In patients with baseline hepatic impairment, the starting dose should be reduced. During treatment, doctors will regularly monitor liver enzyme levels based on clinical indications and the patient's liver function, and adjust the dose or discontinue medication as necessary.

4. Patients with renal impairment: A decrease in glomerular filtration rate may occur in patients receiving bosutinib. Physicians may reduce the starting dose or modify the treatment regimen in patients who develop renal impairment at baseline and during treatment. During treatment, patients should have their renal function monitored regularly, especially in those with pre-existing renal impairment or risk factors for renal dysfunction.

5. Patients with a history of cardiovascular disease: Bosutinib may cause adverse reactions in the cardiovascular system, such as hypertension, bradycardia, etc. For patients with a history of cardiovascular disease, such as hypertension, heart disease, etc., bosutinib should be used with caution, and blood pressure, heart rate and other indicators should be monitored regularly. If serious adverse reactions occur or symptoms continue to worsen, your doctor should be informed promptly and the treatment plan should be adjusted.

In short, before using bosutinib, patients should inform their doctors in detail about their health status, past medical history, and other drugs they are taking. This helps doctors comprehensively assess a patient's treatment risks and develop an appropriate treatment plan. At the same time, patients should use drugs correctly according to the doctor's instructions and receive relevant examinations and monitoring regularly. It is reported that bosutinib is only sold in overseas markets, and the prices of different versions vary. Patients should choose according to their needs.